Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Cancer Med. 2023 Jun;12(11):12084-12094. doi: 10.1002/cam4.5895. Epub 2023 Apr 16.
To clarify the necessity and effect of a single intraoperative instillation of chemotherapy during radical cystectomy.
Patients who underwent radical cystectomy for bladder cancer between January 2013 and April 2019 were retrospectively evaluated and divided into a non-instillation group and an instillation group according to the intraoperative instillation of chemotherapy. Univariate and multivariate Cox regression was used to determine the clinical predictors of overall survival and disease-free survival. Kaplan-Meier analysis and log-rank tests were performed to analyze overall survival and disease-free survival.
Of the 320 patients who were enrolled in the study, 113 underwent radical cystectomy with intraoperative instillation of chemotherapy. Univariate Cox analysis showed that intraoperative instillation was not a risk factor for overall survival or disease-free survival (HR: 1.04, 95% CI: 0.66-1.63, p = 0.864; HR: 1.11, 95% CI: 0.76-1.62, p = 0.602, respectively). As shown in the Kaplan-Meier analysis, no significant differences were noted in overall survival (p = 0.857) and disease-free survival (p = 0.600) between the two groups. A subgroup analysis demonstrated that intraoperative instillation was not associated with a statistically better overall survival and disease-free survival in the nonmuscle invasive (p = 0.852 and 0.836) and muscle-invasive (p = 0.929 and 0.805) patients.
A single intraoperative instillation of chemotherapy during radical cystectomy was not related to better disease-free survival or overall survival. It is unnecessary to consider single instillation of chemotherapy as a regular procedure during radical cystectomy.
阐明在根治性膀胱切除术期间单次术中化疗灌注的必要性和效果。
回顾性评估了 2013 年 1 月至 2019 年 4 月期间接受根治性膀胱切除术治疗膀胱癌的患者,并根据术中化疗灌注情况将其分为非灌注组和灌注组。采用单因素和多因素 Cox 回归分析确定总生存期和无病生存期的临床预测因素。采用 Kaplan-Meier 分析和对数秩检验分析总生存期和无病生存期。
在纳入研究的 320 例患者中,有 113 例患者在根治性膀胱切除术中进行了术中化疗灌注。单因素 Cox 分析显示,术中灌注不是总生存期或无病生存期的危险因素(HR:1.04,95%CI:0.66-1.63,p=0.864;HR:1.11,95%CI:0.76-1.62,p=0.602)。Kaplan-Meier 分析显示,两组患者的总生存期(p=0.857)和无病生存期(p=0.600)差异无统计学意义。亚组分析表明,术中灌注与非肌肉浸润(p=0.852 和 0.836)和肌肉浸润(p=0.929 和 0.805)患者的总生存期和无病生存期的改善无显著相关性。
根治性膀胱切除术中单次化疗灌注与无病生存或总生存无关。在根治性膀胱切除术中,不必考虑单次灌注化疗作为常规手术。